Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

Elon Musk’s Neuralink Enrolls Three Patients For Its Clinical Trial

Daniel Kim Views  

Neuralink, Elon Musk’s brain chip company, announced that three participants will evaluate its device in a study expected to take a few years.

Last year, local media reported that Neuralink planned to register ten patients when applied to the U.S. regulatory agency for clinical trials.

Neuralink is testing its device to allow paralyzed patients to use digital devices by thought alone, which is believed to be helpful for patients with spinal cord injuries.

The Food and Drug Administration (FDA) generally encourages companies to share their clinical trial information for the public good; however, the FDA and the company executives refused to comment on Neuralink.

This research has a primary due date of 2026, while the entire study is expected to be completed by 2031.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LATEST] Latest Stories

  • [James Stavridis] The Gaza peace plan will fail without US troops
  • Arrest warrants issued for 48 suspects brought from Cambodia
  • [Sohn Jie-ae] Yeosu — the ocean at night
  • S. Korea's biggest export promotion fair kicks off ahead of APEC summit
  • Do Seoulites really need e-scooters or e-bikes? The city isn't sure either
  • Top security adviser discusses deepening partnership with deputy NATO chief

Share it on...